Plans to Remove Potentially Carcinogenic Contaminants from Januvia, Janumet Outlined By Merck
Merck indicates it will remove nitrosamine contaminants from Januvia and Janumet by the end of 2023.
Merck indicates it will remove nitrosamine contaminants from Januvia and Janumet by the end of 2023.
Some batches of Januvia, a diabetes drug, contain high levels of nitrosamines which could increase cancer risks, the FDA warns.
A federal judge has again dismissed hundreds of diabetes drug lawsuits alleging medications like Byetta and Januvia can cause pancreatic cancer.
An Illinois appeals court has reinstated two Januvia lawsuits, saying that juries must decide failure to warn claims over pancreatic cancer risks.
A new study warns that older diabetes drugs may increase the risk of heart problems, and suggests doctors use newer medications as second-line treatments.
Another study appears to link Invokana and similar diabetes drugs with an increased risk of leg and foot amputations.
A growing number of lawsuits over claims that Byetta, Victoza and similar diabetes drugs can cause pancreatic cancer are being filed in the wake of a recent decision to reinstate…
A new schedule for Byetta, Januvia and Victoza pancreatic cancer lawsuits sets the first bellwether trial for January 2020.
More than 700 Victoza, Byetta, Januvia and Janumet pancreatic cancer lawsuits have been reinstated by a federal appeals court, overturning a summary judgment that led to their dismissal in 2015.
A new study highlights the diabetic ketoacidosis risk with Invokana, indicating that users of the new generation diabetes drug may be twice as likely to develop this dangerous build up…